Chemical biology and proteomic strategies are rapidly emerging as cost effective yet powerful preclinical approaches for the discovery and identification of novel drugs and targets. Advances in the development and combination of high-quality chemical tools, bioorthogonal techniques, disease-relevant phenotypic systems, chemoinformatics, proteomics and quantitative mass spectrometry, now provide robust and high-throughput workflows for interrogating drug-target-phenotype relationships. These efforts are poised to significantly enrich preclinical discovery programs and are illuminating a new paradigm for the development of novel drugs modulating novel targets.
Cambridge Healthtech Institute’s Chemical Biology and Proteomics for Target Validation will once again gather an interdisciplinary collection of leaders to discuss these emerging tools and strategies to de-risk novel discovery initiatives
KEYNOTE SPEAKERS
From Yeast to Human Neurons and Back Again: Powerful Platforms for Chemical Biology and Target Validation
Susan Lindquist, Ph.D., Member, Whitehead Institute for Biomedical Research; Professor of Biology, Massachusetts Institute of Technology; Investigator, Howard Hughes Medical Institute
FITGE-Based Target Identification for the Connection of Rational Drug Discovery with Phenotypic Screening
Seung Bum Park, Ph.D., Professor, Chemistry, Seoul National University
BioPlex 1.0: An Orfeome-Based, Mass Spectrometry-Driven, Human Protein Interaction Network
Steven P. Gygi, Ph.D., Professor, Cell Biology, Harvard Medical School
Mass Spectrometry-Based Proteomics in Preclinical Drug Discovery
Bernhard Kuster, Ph.D., Professor, Co-Founder and Chair, Proteomics and Bioanalytics, Technische Universität München, OmicScouts GmbH